<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-09-22T14:31:10Z</responseDate><request verb="GetRecord" identifier="oai:www.repository.cam.ac.uk:1810/316345" metadataPrefix="uketd_dc">https://api.repository.cam.ac.uk/server/oai/request</request><GetRecord><record><header><identifier>oai:www.repository.cam.ac.uk:1810/316345</identifier><datestamp>2024-06-26T13:57:27Z</datestamp><setSpec>com_1810_224357</setSpec><setSpec>com_1810_256062</setSpec><setSpec>col_1810_224358</setSpec></header><metadata><uketd_dc:uketddc xmlns:uketd_dc="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:uketdterms="http://naca.central.cranfield.ac.uk/ethos-oai/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">
   <dc:title>Terminal uridyl transferases: TUT4/7-mediated RNA metabolism in cancer</dc:title>
   <dc:identifier xsi:type="dcterms:DOI">10.17863/CAM.63455</dc:identifier>
   <dc:creator>Medhi, Ragini</dc:creator>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">0000000227800708</uketdterms:authoridentifier>
   <uketdterms:advisor>Miska, Eric</uketdterms:advisor>
   <uketdterms:authoridentifier xsi:type="uketdterms:ORCID">000000024450576X</uketdterms:authoridentifier>
   <dcterms:abstract>Nascent RNA is subjected to a wide range of RNA metabolic processes such as non-templated additions of uridines at the 3′ end after it has been transcribed. These additions are catalysed by the terminal uridyl transferases TUT4 and TUT7 (TUT4/7). Defects in TUT4/7-mediated functions result in sterility, failed embryogenesis and susceptibility to viral pathogens. Additionally, TUT4/7 have been shown to be key regulators of the tumorigenic LIN28A/let-7 pathway. However, a full understanding of TUT4/7-mediated mechanisms of RNA control that impinge on tumorigenesis is still missing.

In this thesis, I establish catalytic knockouts of TUT4/7 in two distinct cancer cell types to understand the mechanistic aspects of TUT4/7-mediated regulation in tumorigenesis. I observe cell type specific defects in cancer properties in the TUT4/7 double mutants. As the cell type specific differences in defects could be due to the presence or absence of LIN28A, I integrated the LIN28A cDNA in the LIN28A-negative cancer cell line. This allowed the comparison of TUT4/7-dependent gene expression changes in a LIN28A context. My findings suggest that miRNAs and mRNAs do not generally depend on LIN28A-mediated TUT4/7 regulation. Instead, I find that TUT4/7 can shape the transcriptomic landscape according to the cancer cell type independently of LIN28A.

Furthermore, I provide new examples of emerging compensatory mechanisms that arise upon TUT4/7 loss. I observe that loss of uridylation results in a simultaneous gain in 3′ adenylation. The extent of gain in adenylation is miRNA-specific with some miRNAs overexpressing adenylated isomiRs upon TUT4/7 loss. This might contribute to the observed proliferative defects in the TUT4/7 double mutants.

Finally, I show that TUT4 and TUT7 have non-redundant functions. I identify miRNA targets of TUT7 that are not uridylated by TUT4 and vice versa. I also present ongoing work on the development of an effective technique to identify direct targets of TUT4/7 and to gain a comprehensive view of RNA control mechanisms based on sequence specific features.

Having examined the TUT4/7-mediated regulatory networks at a transcriptome level, my findings show that TUT4/7 is a promising cancer target for an ovarian cancer subtype. However, exploring the biological effects of the novel compensatory mechanisms that emerge upon TUT4/7 loss warrant further study so as to prevent deleterious consequences when targeting TUT4/7 as a potential cancer therapy.</dcterms:abstract>
   <uketdterms:institution>University of Cambridge</uketdterms:institution>
   <dcterms:issued>2020-09-01</dcterms:issued>
   <dc:type>Thesis</dc:type>
   <uketdterms:qualificationlevel>Doctoral</uketdterms:qualificationlevel>
   <uketdterms:qualificationname>Doctor of Philosophy (PhD)</uketdterms:qualificationname>
   <dc:language>eng</dc:language>
   <uketdterms:sponsor>Storm Therapeutics Ltd.</uketdterms:sponsor>
   <dcterms:isReferencedBy xsi:type="dcterms:URI">https://www.repository.cam.ac.uk/handle/1810/316345</dcterms:isReferencedBy>
   <dc:identifier xsi:type="dcterms:URI">https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/a94e2999-cb2c-445b-a897-35a25fd6f53e/download</dc:identifier>
   <uketdterms:checksum xsi:type="uketdterms:MD5">4616c14a1edb525f3922f5cf90ccce6f</uketdterms:checksum>
   <dcterms:license>https://apollo8-f-pro.lib.cam.ac.uk/bitstreams/d0cddbfe-7946-4a3c-9b17-2b1dc085cb4e/download</dcterms:license>
   <uketdterms:checksum xsi:type="uketdterms:MD5">353adac0d1ebdfd65ab16480263c3c87</uketdterms:checksum>
   <dc:rights>https://www.rioxx.net/licenses/all-rights-reserved/</dc:rights>
   <dc:subject>Cancer</dc:subject>
   <dc:subject>Tumorigenesis</dc:subject>
   <dc:subject>RNA</dc:subject>
   <dc:subject>RNA metabolism</dc:subject>
</uketd_dc:uketddc>
</metadata></record></GetRecord></OAI-PMH>